Pfizer has a new study ongoing on PF-07868489, a recombinant human IgG1 antibody that targets bone morphogenetic protein 9 (BMP9) and is administered through subcutaneous route for the treatment of PAH.
PF-07868489 is currently in Phase 2 development and has received Orphan Drug designation in the US.
The study (NCT06137742) has two parts:
Part A: An investigator- and participant-blind, sponsor-open, placebo-controlled, single ascending dose study to assess the safety, tolerability, and pharmacokinetics (PK) of PF-07868489 in healthy adult participants.
Part B: A 24-week, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, PK, and pharmacodynamics (PD) of PF-07868489 in adult participants with pulmonary arterial hypertension.
Recruitment is ongoing and there are 60 sites including in Europe. Read more at this link on the Pfizer website.